2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

Acquired Resistance ◽

Phase 2 ◽

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Case Medical Research ◽

10.31525/ct1-nct04247256 ◽

2020 ◽

Author(s):

Keyword(s):

Colorectal Cancer ◽

Acquired Resistance ◽

Phase 2 ◽

Phase 2 Trial

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

Cancer ◽

10.1002/cncr.30967 ◽

2017 ◽

Vol 124 (4) ◽

pp. 688-697

Author(s):

Neal J. Meropol ◽

Yang Feng ◽

Jean L. Grem ◽

Mary F. Mulcahy ◽

Paul J. Catalano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Research ◽

Thymidylate Synthase ◽

Research Group ◽

Treatment Selection ◽

Phase 2 ◽

Abstract 4461: Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC)

10.1158/1538-7445.sabcs18-4461 ◽

2019 ◽

Author(s):

Cyril Y. Ramathal ◽

Erin Murphy ◽

Elizabeth Asque ◽

Arne Jason Grundstad ◽

Peter Ansell ◽

...

Keyword(s):

Colorectal Cancer ◽

Circulating Tumor Dna ◽

Phase 2 ◽

Genomic Alterations ◽

Phase 2 Study ◽

Tumor Dna

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

British Journal of Cancer ◽

10.1038/s41416-019-0537-z ◽

2019 ◽

Vol 121 (5) ◽

pp. 378-383 ◽

Cited By ~ 1

Author(s):

Elena Elez ◽

Carles Pericay ◽

Manuel Valladares-Ayerbes ◽

Inmaculada Bando ◽

Maria Jose Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Salvage Therapy ◽

Phase 2 ◽

Wild Type ◽

Exon 2 ◽

Phase 2 Study ◽

Colorectal Cancer Patients ◽

Kras Exon

PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdw335.22 ◽

2016 ◽

Vol 27 ◽

pp. iv46

Author(s):

B. Daniele ◽

R.V. Iaffaioli ◽

C. Chiara ◽

E. Maiello ◽

G. Rosati ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Two Stage ◽

A multicenter phase 2 study of irinotecan (CPT-11) and doxifluridine (5’-DFUR), an intermediate form of capecitabine, for metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3698 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3698-3698

Author(s):

M. Ikenaga ◽

T. Kato ◽

H. Mishima ◽

M. Fukunaga ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Intermediate Form ◽

Phase 2 ◽

Multicenter Phase ◽

Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.3629 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 3629-3629 ◽

Cited By ~ 4

Author(s):

Fernando Rivera ◽

Lee Steven Schwartzberg ◽

Meinolf Karthaus ◽

Gianpiero Fasola ◽

Jean-Luc Canon ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

First Line ◽

Anti Vegf ◽

ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.3557 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 3557-3557 ◽

Cited By ~ 7

Author(s):

Nilofer Saba Azad ◽

Keisuke Shirai ◽

Autumn Jackson McRee ◽

Mateusz Opyrchal ◽

Douglas Buckner Johnson ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients

Advances in Therapy ◽

10.1007/s12325-012-0002-3 ◽

2012 ◽

Vol 29 (3) ◽

pp. 287-296

Author(s):

Eishi Baba ◽

Hiromitsu Fujishima ◽

Akitaka Makiyama ◽

Keita Uchino ◽

Risa Tanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase 2 ◽

Phase 2 Study ◽

Colorectal Cancer Patients

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

Cancer ◽

10.1002/cncr.31309 ◽

2018 ◽

Vol 124 (11) ◽

pp. 2337-2346 ◽

Cited By ~ 16

Author(s):

Michael J. Pishvaian ◽

Rebecca S. Slack ◽

Wei Jiang ◽

A. Ruth He ◽

Jimmy J. Hwang ◽

...

Keyword(s):

Colorectal Cancer ◽

Parp Inhibitor ◽

Phase 2 ◽

Phase 2 Study ◽

Heavily Pretreated